Claudio Albrecht, co-founder of APP, was invited as a key note speaker at the world generic congress in Barcelona 2016. The topic of his speech was the M&A activity in the generics industry. Scientific progress will force generics to spend more money for R&D and Sales and Marketing. Product categories like Biosimilars, Immunotherapies or Genetherapies paired with developments in digital health require much more investment than classic commodity generics. This will foster further consolidation among small and mid sized generic companies – Claudio Albrecht said.